Given that the binding of S100A9 to RAGE in the cancer cell is the trigger to the activation of nuclear factor kappa B (NF-κB) signaling and JunB, which underlies the resistance mechanism to radiotherapy, this therapeutic approach paradoxically desensitizes metastatic cells to it. This evidence concerns the gene S100A9 and cancer.